Type 1 diabetes affects millions worldwide and requires lifelong insulin injections due to the autoimmune destruction of insulin-producing cells in the pancreas. A new study from the Garvan Institute of Medical Research tested metformin on 40 adults with long-term type 1 diabetes in the Insulin Resistance in Type 1 Diabetes Managed with Metformin (INTIMET) study. Participants received either metformin or a placebo for six months. While metformin did not reduce insulin resistance as anticipated, those taking it used about 12% less insulin daily while maintaining stable blood sugar levels. Dr. Jennifer Snaith, an endocrinologist and co-lead of the study, emphasized the importance of reducing insulin usage due to its mental and physical burden on patients. The study suggests that metformin may work through mechanisms related to the gut microbiome, prompting further investigation into its effects on gut flora in type 1 diabetes patients. This research offers hope for more effective management of type 1 diabetes with a widely available and inexpensive medication.